Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to trans... Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. Mehr anzeigen
Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company...
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence PR Newswire CAMBRIDGE, Masss. and LONDON, Oct...
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass., Oct. 3, 2024 CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship...
Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care...
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1951 | -19.51 | 1 | 1.01 | 0.75 | 505091 | 0.79703168 | CS |
| 4 | -0.6751 | -45.6148648649 | 1.48 | 1.51 | 0.75 | 328412 | 1.00273137 | CS |
| 12 | -0.6751 | -45.6148648649 | 1.48 | 1.69 | 0.75 | 288328 | 1.13968082 | CS |
| 26 | -1.4151 | -63.7432432432 | 2.22 | 2.625 | 0.75 | 348487 | 1.66801152 | CS |
| 52 | -1.0951 | -57.6368421053 | 1.9 | 6.3 | 0.75 | 792139 | 3.92232467 | CS |
| 156 | -20.0251 | -96.1358617379 | 20.83 | 20.83 | 0.75 | 350184 | 4.38029537 | CS |
| 260 | -21.2951 | -96.357918552 | 22.1 | 31.41 | 0.75 | 327397 | 4.90497591 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
